Collegium Pharmaceutical, Inc.

NasdaqGS:COLL Stock Report

Market Cap: US$1.3b

Collegium Pharmaceutical Management

Management criteria checks 3/4

Collegium Pharmaceutical's CEO is Joe Ciaffoni, appointed in Jul 2018, has a tenure of 5.67 years. total yearly compensation is $6.92M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 0.47% of the company’s shares, worth $5.92M. The average tenure of the management team and the board of directors is 5.1 years and 9.6 years respectively.

Key information

Joe Ciaffoni

Chief executive officer

US$6.9m

Total compensation

CEO salary percentage10.9%
CEO tenure5.7yrs
CEO ownership0.5%
Management average tenure5.1yrs
Board average tenure9.6yrs

Recent management updates

Recent updates

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24
These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05
There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Aug 09
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Mar 10
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Oct 18
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Jun 24
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Jun 12

Collegium Pharmaceutical: Thoughts After Another Strategic Move

Feb 20

There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

Feb 15
There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

Oct 30
We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

Sizing Up Collegium Pharmaceuticals

Oct 04

Collegium Pharmaceutical: Moving Closer To The Top

Jul 12

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Is Looking A Bit Stretched At The Moment

May 14
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Is Looking A Bit Stretched At The Moment

Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings

May 13
Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings

We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt

May 01
We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt

CEO Compensation Analysis

How has Joe Ciaffoni's remuneration changed compared to Collegium Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

US$48m

Sep 30 2023n/an/a

US$9m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$7mUS$752k

-US$25m

Sep 30 2022n/an/a

-US$43m

Jun 30 2022n/an/a

-US$35m

Mar 31 2022n/an/a

US$43m

Dec 31 2021US$7mUS$713k

US$72m

Sep 30 2021n/an/a

US$104m

Jun 30 2021n/an/a

US$107m

Mar 31 2021n/an/a

US$42m

Dec 31 2020US$6mUS$654k

US$27m

Sep 30 2020n/an/a

US$18m

Jun 30 2020n/an/a

US$198k

Mar 31 2020n/an/a

-US$13m

Dec 31 2019US$4mUS$618k

-US$23m

Sep 30 2019n/an/a

-US$11m

Jun 30 2019n/an/a

-US$22m

Mar 31 2019n/an/a

-US$30m

Dec 31 2018US$4mUS$536k

-US$39m

Sep 30 2018n/an/a

-US$66m

Jun 30 2018n/an/a

-US$62m

Mar 31 2018n/an/a

-US$70m

Dec 31 2017US$3mUS$265k

-US$75m

Compensation vs Market: Joe's total compensation ($USD6.92M) is above average for companies of similar size in the US market ($USD5.09M).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.


CEO

Joe Ciaffoni (51 yo)

5.7yrs

Tenure

US$6,917,530

Compensation

Mr. Joseph J. Ciaffoni, also known as Joe, has been Chief Executive Officer and Director of Collegium Pharmaceutical, Inc. since July 1, 2018 and also has been its President since July 2018. Mr. Ciaffoni s...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Heffernan
Co-Founder & Chairman20.4yrsUS$334.28k0.044%
$ 555.6k
Joseph Ciaffoni
President5.7yrsUS$6.92m0.47%
$ 5.9m
Colleen Tupper
Executive VP & CFO2.8yrsUS$2.32m0.12%
$ 1.6m
Shirley Kuhlmann
Executive VP6yrsUS$2.43m0.14%
$ 1.8m
Scott Dreyer
Executive VP & Chief Commercial Officer5.7yrsUS$2.22m0.10%
$ 1.3m
Thomas Smith
Executive VP & Chief Medical Officer2yrsUS$692.92k0.029%
$ 366.2k
Christopher James
Vice President of Investor Relationsno datano datano data
Bart Dunn
Executive Vice President of Strategy & Corporate Development4.5yrsno datano data
Scott Sudduth
Head of Technical Operations2.4yrsno datano data

5.1yrs

Average Tenure

51yo

Average Age

Experienced Management: COLL's management team is seasoned and experienced (5.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Heffernan
Co-Founder & Chairman20.4yrsUS$334.28k0.044%
$ 555.6k
Joseph Ciaffoni
President5.7yrsUS$6.92m0.47%
$ 5.9m
John Freund
Independent Director10.1yrsUS$302.28k0.12%
$ 1.5m
Garen Bohlin
Independent Director9.2yrsUS$303.28k0.0070%
$ 89.5k
Gino Santini
Lead Independent Director11.7yrsUS$312.16k0.080%
$ 1.0m
Bill McCarberg
Scientific Advisorno datano datano data
Robert Dworkin
Scientific Advisorno datano datano data
Lynn Webster
Scientific Advisorno datano datano data
John Fallon
Independent Director7.8yrsUS$299.62k0.073%
$ 926.4k
Cynthia McCormick
Scientific Advisorno datano datano data
Richard Rauck
Scientific Advisorno datano datano data
Charles Argoff
Scientific Advisorno datano datano data

9.6yrs

Average Tenure

67.5yo

Average Age

Experienced Board: COLL's board of directors are considered experienced (9.6 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.